Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Molecular aspects of medicine
2025
|
| Subjects: | |
| Online Access: | https://pubmed.ncbi.nlm.nih.gov/41218566/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1868266127743778817 |
|---|---|
| author | Jimeno, Jose Varona, Jose Felipe Lopez-Martin, Jose A Izquierdo-Useros, Nuria Molina Molina, Elisa Guisado-Vasco, Pablo Sachse, Martin Risco, Cristina Losada, Alejandro Fudio, Salvador Luepke, Erik Nieto, Antonio Gomez, Javier Aviles, Pablo Cuevas, Carmen Bouhaddou, Mehdi Sola, Isabel Krogan, Nevan J Enjuanes, Luis Fernandez-Sousa, Jose M GarcÍa-Sastre, Adolfo White, Kris |
| author_facet | Jimeno, Jose Varona, Jose Felipe Lopez-Martin, Jose A Izquierdo-Useros, Nuria Molina Molina, Elisa Guisado-Vasco, Pablo Sachse, Martin Risco, Cristina Losada, Alejandro Fudio, Salvador Luepke, Erik Nieto, Antonio Gomez, Javier Aviles, Pablo Cuevas, Carmen Bouhaddou, Mehdi Sola, Isabel Krogan, Nevan J Enjuanes, Luis Fernandez-Sousa, Jose M GarcÍa-Sastre, Adolfo White, Kris Jimeno, Jose Varona, Jose Felipe Lopez-Martin, Jose A Izquierdo-Useros, Nuria Molina Molina, Elisa Guisado-Vasco, Pablo Sachse, Martin Risco, Cristina Losada, Alejandro Fudio, Salvador Luepke, Erik Nieto, Antonio Gomez, Javier Aviles, Pablo Cuevas, Carmen Bouhaddou, Mehdi Sola, Isabel Krogan, Nevan J Enjuanes, Luis Fernandez-Sousa, Jose M GarcÍa-Sastre, Adolfo White, Kris |
| collection | PubMed - marine biology |
| contents | Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor. Jimeno, Jose Varona, Jose Felipe Lopez-Martin, Jose A Izquierdo-Useros, Nuria Molina Molina, Elisa Guisado-Vasco, Pablo Sachse, Martin Risco, Cristina Losada, Alejandro Fudio, Salvador Luepke, Erik Nieto, Antonio Gomez, Javier Aviles, Pablo Cuevas, Carmen Bouhaddou, Mehdi Sola, Isabel Krogan, Nevan J Enjuanes, Luis Fernandez-Sousa, Jose M GarcÍa-Sastre, Adolfo White, Kris Humans Depsipeptides SARS-CoV-2 Antiviral Agents COVID-19 Peptides, Cyclic Animals COVID-19 Drug Treatment Pandemics Betacoronavirus Drug Repositioning Coronavirus Infections Clinical Trials as Topic Pneumonia, Viral Selective pressures in the ocean promote the evolution of potent molecules that may be useful in therapeutic settings. Tunicates provide a rich source of bioactive molecules that have been shown to have anti-neoplastic and anti-microbial activities. Plitidepsin, a natural marine cyclic depsipeptide originally isolated from the tunicate Aplidium albicans, was originally developed as an anti-tumor drug, and has been approved for use in Australia in patients with advanced pretreated myeloma. Early in the SARS-CoV-2 pandemic, plitidepsin was shown to have potent preclinical efficacy against the virus, suggesting that it could be repurposed for the treatment of COVID-19. This review summarizes the clinical development of plitidepsin first as an anti-tumor drug, before providing a recapitulation of current efforts to repurpose the molecule as an antiviral therapy. The pharmacokinetic and pharmacodynamic data on plitidepsin will be analyzed, and the various experimental lines of evidence in support of the molecule's multifactorial mechanism of action will be explored. Finally, the available data on the use of plitidepsin in patients with COVID-19 will be presented, including results from a Phase I proof-of-concept study, real-world data from immunocompromised patients, and a look of results from a Phase III clinical trial that confirms the working hypothesis. |
| format | Artículo científico |
| id | pubmed_41218566 |
| institution | PubMed |
| language | en |
| publishDate | 2025 |
| publisher | Molecular aspects of medicine |
| record_format | pubmed |
| spellingShingle | Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor. Jimeno, Jose Varona, Jose Felipe Lopez-Martin, Jose A Izquierdo-Useros, Nuria Molina Molina, Elisa Guisado-Vasco, Pablo Sachse, Martin Risco, Cristina Losada, Alejandro Fudio, Salvador Luepke, Erik Nieto, Antonio Gomez, Javier Aviles, Pablo Cuevas, Carmen Bouhaddou, Mehdi Sola, Isabel Krogan, Nevan J Enjuanes, Luis Fernandez-Sousa, Jose M GarcÍa-Sastre, Adolfo White, Kris Humans Depsipeptides SARS-CoV-2 Antiviral Agents COVID-19 Peptides, Cyclic Animals COVID-19 Drug Treatment Pandemics Betacoronavirus Drug Repositioning Coronavirus Infections Clinical Trials as Topic Pneumonia, Viral Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor. Jimeno, Jose Varona, Jose Felipe Lopez-Martin, Jose A Izquierdo-Useros, Nuria Molina Molina, Elisa Guisado-Vasco, Pablo Sachse, Martin Risco, Cristina Losada, Alejandro Fudio, Salvador Luepke, Erik Nieto, Antonio Gomez, Javier Aviles, Pablo Cuevas, Carmen Bouhaddou, Mehdi Sola, Isabel Krogan, Nevan J Enjuanes, Luis Fernandez-Sousa, Jose M GarcÍa-Sastre, Adolfo White, Kris Humans Depsipeptides SARS-CoV-2 Antiviral Agents COVID-19 Peptides, Cyclic Animals COVID-19 Drug Treatment Pandemics Betacoronavirus Drug Repositioning Coronavirus Infections Clinical Trials as Topic Pneumonia, Viral Selective pressures in the ocean promote the evolution of potent molecules that may be useful in therapeutic settings. Tunicates provide a rich source of bioactive molecules that have been shown to have anti-neoplastic and anti-microbial activities. Plitidepsin, a natural marine cyclic depsipeptide originally isolated from the tunicate Aplidium albicans, was originally developed as an anti-tumor drug, and has been approved for use in Australia in patients with advanced pretreated myeloma. Early in the SARS-CoV-2 pandemic, plitidepsin was shown to have potent preclinical efficacy against the virus, suggesting that it could be repurposed for the treatment of COVID-19. This review summarizes the clinical development of plitidepsin first as an anti-tumor drug, before providing a recapitulation of current efforts to repurpose the molecule as an antiviral therapy. The pharmacokinetic and pharmacodynamic data on plitidepsin will be analyzed, and the various experimental lines of evidence in support of the molecule's multifactorial mechanism of action will be explored. Finally, the available data on the use of plitidepsin in patients with COVID-19 will be presented, including results from a Phase I proof-of-concept study, real-world data from immunocompromised patients, and a look of results from a Phase III clinical trial that confirms the working hypothesis. |
| title | Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor. |
| topic | Humans Depsipeptides SARS-CoV-2 Antiviral Agents COVID-19 Peptides, Cyclic Animals COVID-19 Drug Treatment Pandemics Betacoronavirus Drug Repositioning Coronavirus Infections Clinical Trials as Topic Pneumonia, Viral |
| url | https://pubmed.ncbi.nlm.nih.gov/41218566/ |